Loading...
•
Dec 31, 2019
TherapeuticsMD Q4 2019 Earnings Report
Reported financial results for the full-year and fourth quarter ended December 31, 2019, and provided 2020 financial guidance.
Key Takeaways
TherapeuticsMD announced Q4 2019 net product revenue of $15.9 million, exceeding the company's financial guidance. Full-year 2019 total net product revenue reached $34.1 million, hitting the top end of the financial guidance. The company launched ANNOVERA and expects full-year 2020 net product revenue of $90 million to $110 million.
Net product revenue for Q4 2019 increased 94% to $15.9 million compared to Q3 2019.
ANNOVERA achieved net revenue of $5.8 million in Q4 2019, with an average net revenue per unit of approximately $1,350.
IMVEXXY net revenue for Q4 2019 increased by 33% to $6.3 million compared to Q3 2019, with approximately 123,000 prescriptions dispensed and an average net revenue per unit of approximately $51.
BIJUVA net revenue for Q4 2019 increased 147% to $1.2 million compared to Q3 2019, with approximately 22,000 prescriptions dispensed and an average calculated net revenue per unit of $56.
TherapeuticsMD
TherapeuticsMD
Forward Guidance
The company projects product net revenue for 2020 will be between $90 million to $110 million. The company projects that product net revenue during the second half of the year will be significantly larger than the first half with the majority of 2020 product net revenue coming from ANNOVERA and IMVEXXY.
Positive Outlook
- Product net revenue for 2020 is projected to be between $90 million and $110 million.
- Second half of the year revenue is expected to be significantly larger than the first half.
- Majority of 2020 product net revenue is expected from ANNOVERA and IMVEXXY.
- Achievement of $11 million in net revenues from IMVEXXY, BIJUVA, and ANNOVERA for the fourth quarter of 2019.
- Company received the second tranche of funding under its financing agreement with TPG Specialty Lending, Inc. in the amount of $50 million.
Challenges Ahead
- High deductible and annual copay resets will impact first quarter of 2020 revenue for its menopause products.
- First quarter 2020 product net revenue is expected to come in below fourth quarter 2019 product net revenue.
- Net loss for the full-year 2019 was $176.1 million.
- Net loss for the fourth quarter of 2019 increased to $49.4 million.
- The company expects sales and marketing expenses to continue to increase as it continues the launch of BIJUVA and ANNOVERA and continues to support its growing business and commercialization of its products.